Results 41 to 50 of about 9,061 (176)
Molecular Oncology, EarlyView.We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee +3 more
wiley +1 more source
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers [PDF]
, 2023 Cyclin-dependent kinases 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC).
Bui, Tuyen N +14 more
core +1 more source
Regulatory harmonization: Evolution, globalization and future directions
British Journal of Clinical Pharmacology, EarlyView.Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm +2 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian +12 more
wiley +1 more source
Abemaciclib: First Global Approval
, 2018 Funding: The preparation of this review was not supported by any external funding.Conflicts of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article.
Esther Kim (2996622)
core +1 more source
Abemaciclib-induced Lichenoid Dermatitis: A Rare Case Report
Clinical Dermatology ReviewAbemaciclib is an oral cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) that plays a key role in treating hormone-sensitive HER2-negative metastatic breast cancer. Abemaciclib, due to its higher selectivity for CDK4 tends to cause fewer hematologic issues,
Kallolinee Samal +4 more
doaj +1 more source
Journal of Applied Toxicology, EarlyView.ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü +3 more
wiley +1 more source
The Prostate, EarlyView.ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento +15 more
wiley +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott +8 more
wiley +1 more source
, 2019 Supplemental figure 7: (A) GR50 comparison of Mia PaCa2 (top) or Panc-1 (bottom) parental cells, and their respective "chronic" abemaciclib therapy cells once treated with abemaciclib.
Liang Xu (102656) +14 more
core +1 more source